Cardiovascular diseases in pregnancy

1.Heenan AP, Wolfe LA, Davies GA, McGrath MJ. Effects of human pregnancy on fluid regulation responses to short-term exercise. J Appl Physiol 2003; 95: 2321-2327.

2.Chapman AB, Abraham WT, Zamudio S et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54: 2056-2063.

3.Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21: 514-550.

4.Presbitero P, Contrafatto I. Pregnancy and the Heart. In: Dalla Volta S (ed). Cardiology. 2. ed. London: McGraw-Hill 1999: 795-798.

5.Král J. Kardiovaskulární onemocnění v těhotenství. In: Aschermann M (ed). Kardiologie. 1. ed. Praha: Galén 2004: 1357-1368.

6.Oakley C, Warnes C. Heart Disease in Pregnancy. 2. ed. London: Blackwell BMJ Books 2007.

7.Elkayam U, Gleicher A. Cardiac Problems in Pregnancy. 3. ed. New York: Wiley-Liss 1998.

8.Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in early pregnancy. Obstet Gynecol 2001; 97: 669-672.

9.Silversides CK, Colman JM. Physiological changes in pregnancy. In: Oakley C, Warnes C (eds). Heart Disease in Pregnancy. 2. ed. London: Blackwell BMJ Books 2007: 7-16.

10.Kametas NA, McAuliffe F, Krampl E et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol 2003; 102: 806.

11.Siu SC, Sermer M, Colman JM et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104: 515.

12.Oakley C, Child A, Iung B, Presbitero P et al. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus dokument on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-781.

13.Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48: e1.

14.Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230.

15.Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: Maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol 1998; 105: 921-922.

16.Khairy P, Ouyang DW, Fernandes SM et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006; 113: 517-524.

17.Perloff JK. The Clinical Recognition of Congenital Heart Disease. 5. ed. Philadelphia: WB Saunders 2003.

18.Popelová J. Vrozené srdeční vady v dospělosti. 1. ed. Praha: Grada Publishing 2003.

19.Drenthen W, Pieper PG, Roos-Hesselink JW et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49: 2303-2311.

20.Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol 1998; 23: 125.

21.Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003; 91: 1382.

22.Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-196.

23.Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol 2005; 46: 403-410.

24.Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335: 407.

25.Sephton V, Farquharson RG, Topping J et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-1311.

26.Cotrufo M, De Feo M, De Santo LS et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99: 35-40.

27.Schaefer C, Hannemann D, Meister R et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95: 949-957.

28.Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl 3): 627S-644S.

29.Wilson W, Taubert KA, Gewitz M et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116: 1736-1754.

30.Mugo M, Govindarajan G, Kurukulasuria LR et al. Hypertension in pregnancy. Curr Hypertens Rep 2005; 7(5): 348-354.

31.Levine RJ, Ewell MG, Hauth JC et al. Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥ 15 mmHg to a level > 90 mmHg in association with proteinuria. Am J Obstet Gynecol 2000; 183: 787-792.

32.Mancia G, De Backer G et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertenison (ESH) and of the European Society of Cardiology. Europ Heart J 2007; 28: 1462-1536.